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Cardiovascular function relies on complex servo-controlled regulation mechanisms that involve
both fast-acting feedback responses and long-lasting adaptations affecting the gene expression.
The adrenergic system, with its speci®c receptor subtypes and intracellular signalling cascades
provides the major regulatory system, while the parasympathetic system plays a minor role. At
the molecular level, Ca2+ acts as the general signal trigger for the majority of cell activities
including contraction, metabolism and growth. During recent years, important new results
have emerged allowing an integrated view of how the multifarious Ca2+-signalling mechanisms
transmit adrenergic impulses to intracellular target sites. These insights into cellular and
molecular mechanisms are pivotal in improving pharmacological control of the sympathetic
responses to surgical trauma and perioperative stress. They are examined in detail in this
review, with particular emphasis being given to the differences in intracellular signalling
between cardiomyocytes and vascular smooth muscle cells.
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Heart function, in terms of contractile force (inotropy),
beating frequency (heart rate) and blood supply (vascular
tone), relies on a three-tiered control system: (i) immediate
and fast feedback responses of the cardiac tissue to the
actual mechanical load; (ii) regulation of cardiac perform-
ance by the autonomous nervous system involving humoral
primary messengers affecting the intracellular signalling
systems; and (iii) long-term adaptation to altered
physiological and pathological conditions produced by
changes in gene expression. The ®rst two modes of
regulation are partially overlapping and primarily depend
on the sympathetic nervous system. Repetitive peak
responses, as they occur perioperatively, are part of the
life-supporting adrenergic drive, which, however, may turn
into potentially life-threatening maladaptation. Gaining
control over sympathetic nervous system activity by blunt-
ing the adrenergic responses to the surgical trauma and
perioperative stress is an important task in anaesthetic
practice. The present review summarizes substantially new
experimental results on adrenergic cellular and molecular
mechanisms. Because of limitations of space, reviews will
often be cited where further references to the primary
literature can be found. Unless otherwise stated, the
molecular characteristics pertain to the human protein
species. Clinical aspects of the individual sympatho-
modulatory therapies in perioperative medicine, based on
these new experimental ®ndings, will be presented in the
article `Sympatho-modulatory therapies in perioperative
medicine' by Zaugg and Schaub in this issue.
Adrenergic receptor subtype-speci®c
signalling via G-proteins
Acute and long-term regulation of myocardial function,
including heart rate, systolic and diastolic function and
metabolism, are primarily governed by the b1- and b2-
adrenergic receptor (AR) signalling pathways. A functional
role for the a-AR is less well established, although positive
and negative inotropic effects have been attributed to
speci®c a-AR subtypes, particularly in cardiomyopathies
and heart failure.11 24 43 54 69 72 76 The human AR
superfamily consists of nine subtypes originating from
different genes (with single polypeptide chains varying in
length from 408 to 572 amino acid residues): a1A, a1B, a1D,
a2A, a2B, a2C, b1, b2 and b3. All these cell surface receptors
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contain an extracellular N-terminus, seven transmembrane
a-helices (TM1±TM7) and an intracellular C-terminal
region. They are all able to couple to the guanine
nucleotide-binding G-proteins and are therefore called G-
protein-coupled receptors (GPCRs). The extracellular
N-terminal region, together with the extracellular loops
between the TM2 and TM7 helices, contributes to the
formation of the extracellular ligand binding pocket,
whereas the amino acid sequences of the intracellular
domains (loops) between the TMs, together with the
proximal portion of the C-terminal region, are involved in
mediating G-protein coupling. Activated G-proteins trans-
mit signals to speci®c intracellular targets (Fig. 1). The
downstream signalling pathways involve sequential protein
phosphorylation cascades that ultimately affect targets in
the cytoplasm or operate via transcriptional factors affecting
gene expression. A second group of enzymes, the protein
phosphatases, are responsible for dephosphorylation and
termination of signalling. All intracellular signalling path-
ways are interconnected and form a robust network with
ample redundancy. This complexity allows subtle modula-
tion of individual cellular responses.
The GPCRs constitute the third-largest family of genes
present in the human genome, and represent a central target
structure for drug development. However, their therapeutic
use is often limited by unwanted side-effects. Some of these
derive from the binding of the drugs to related receptor
subtypes.11 72 74 76 90 In the normal human myocardium, b1-
AR is the most abundant species (70±80%), a1 and b2
account for over 10% each, and b3 is low (around 1%).
However, heart failure caused by either dilated or ischaemic
cardiomyopathy is accompanied by selective down-regula-
tion of b1-AR, entailing a relative increase in both a1A and
b2, which together amount to ~50% of total ARs. In the
failing heart, the b3-AR protein concentration increases by a
factor of 3.
ARs couple to the heterotrimeric G-protein complex (Ga,
Gb, Gg) on the inner side of the cell membrane.3 12 60 76 94
Fig 1 Sympathetic and parasympathetic signalling cascades of G-protein coupled receptors down to the level of cellular responses.8 11 20 54 60 63 76 98 99
Note the intimate crosstalk between the various signalling pathways. Lines with blunted ends (=) indicate inhibition. AC=adenylyl cyclase;
ACh=acetylcholine; AR=adrenergic receptor; cAMP=cyclic AMP; cGMP=cyclic GMP; DAG=diacylglycerol; ET1=endothelin receptor-1;
GC=guanylyl cyclase; Gai, Gas, Gaq, Gbg=G-protein subunits; IP3=inositol trisphosphate; M2=muscarinic acetylcholine receptor; MAPK=mitogen
activated protein kinase; NOS=nitric oxide synthase; PDK1=phosphoinositide-dependent kinase-1; PI3K=phosphoinositide-3 kinase; PKA, PKB, PKC,
PKG=target-speci®c serine±threonine protein kinases; PLC=phospholipase C; Ras=small monomeric GTPase; RNOS=reactive nitric oxide species.
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Upon activation, the Ga-subunit hydrolyses guanosine
triphosphate (GTP) and dissociates from the complex,
leaving the bg-subunits as undissociable heterodimer
(Fig. 1). Currently there are 20 known Ga, six Gb and
eleven Gg subunits. When activated, all three a1-ARs
interact with the pertussis toxin-insensitive Gaq component,
which follows the main signalling route via phospholipase C
(PLC) leading to diacylglycerol (DAG), producing activ-
ation of protein kinase C (PKC) and inositol trisphosphate
(IP3) for the liberation of Ca2+ from the sarcoplasmic
reticulum (SR). All three a2-ARs couple to the pertussis
toxin-sensitive Gai, leading to inhibition of the integral
membrane protein adenylyl cyclase (AC), activation of K+-
channels, and inhibition of the sarcolemmal L-type Ca2+
entry channels (DHPR). This is in contrast to the b-ARs,
which are more variable in their coupling to G-proteins
(Fig. 1). The b1-AR couples almost exclusively to Gas,
inducing positive inotropy (increased contractile amplitude)
and positive lusitropy (enhanced relaxation). Its canonical
signalling pathways involve activation of AC and protein
kinase A (PKA). b2- and b3-ARs are both able to signal via
Gas, Gai or Gaq depending on the physiological or
pathophysiological conditions (different states with regard
to catecholamines, in¯ammatory cytokines and angiotensin-
II). The Gas and Gaq protein families have de®ned main
effector pathways: the AC and the PLC pathways, respect-
ively. The Gai protein family is more amorphous and its
signalling ¯ows equally through both the Gai and the Gbg
complex, affecting several different downstream signalling
pathways. Gaq-dependent signalling by the heterodimeric
Gbg to the phosphoinositol-3 kinase (PI3K) pathway was
recently established in cardiac hypertrophy.20
Fig 2 Interrelation of adrenergic and acetylcholine G-protein-coupled receptors (GPCR) with the global signalling pathways of the
cardiomyocyte.5 20 33 53 55 71 79 99 Open arrows indicate cytoplasmic effects. cAMP=cyclic AMP; Cdc42, Ras, Rac=small monomeric GTPases;
CR=cytokine receptor; CT-1=cardiotrophin-1; DAG=diacylglycerol; EGF=epidermal growth factor; ERK=extracellular signal-regulated kinase;
FGF=®broblast growth factor; Gi, Gs, Gq, Gbg=G-protein subunits; gp130=130 kDa leucine-rich protein; IGF-I=insulin-like growth factor-1; IL-1b,
interleukin-1b; IL-6=interleukin-6; IP3=inositol trisphosphate; JAK=Janus kinase; JNK=c-Jun N-terminal kinase; LIF=leukaemia inhibitory factor;
MAPK=mitogen-activated protein kinase; MEK=mitogen-activated ERK-activating kinase; MEKK=MEK kinase; MKK=MAPK kinase;
MKKK=MAPKK kinase; p38=p38 MAP kinase; PAK=p21-activated kinase; PDGF=platelet-derived growth factor; PDK1=phosphoinositide-
dependent kinase-1; PI3K=phosphoinositide-3 kinase; PIP2=phosphatidylinositol bisphosphate; PKA, PKB, PKC=target-speci®c serine±threonine
protein kinases; PLC=phospholipase-C; Raf=a kinase of the MKKK family; RSTK=receptor serine±threonine kinase; RTK=receptor tyrosine kinase;
Smad=TFGb signalling protein; STAT=signal transducer and activator of transcription; TAK1=TGFb-activated kinase-1; TGFb=transforming growth
factor-b.
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AC is an integral membrane protein with 12 transmem-
brane helices and a molecular weight of ~130 kDa.25 26 65 At
least nine isoforms of the AC exist (AC1±AC9); AC5 is
speci®cally expressed in cardiomyocytes, whereas AC6
occurs in heart cells other than myocytes. Additional
isoforms are also expressed in the heart, but to a lesser
degree. In addition to its regulation by G-proteins
(stimulatory Gas and inhibitory Gai), PKC further stimu-
lates and PKA inhibits the activity of AC isoforms.
Furthermore, high Ca2+ during sustained cell activity
inhibits AC5 and AC6, establishing a negative feedback
loop. The ®ne tuning in the regulation of AC is of particular
signi®cance as its activity is rate-limiting in adrenergic
signal transmission. PLC is a peripheral membrane protein
at the cytoplasmic side, hydrolysing phosphatidylinositol
4,5-bisphosphate (PIP2) to DAG and IP3 (Figs 2 and 3). It
has an absolute requirement for Ca2+ bound to the active site
and comprises three types: PLCb (150 kDa), stimulated by
G-proteins; PLCg (150 kDa), stimulated by receptor
tyrosine kinases; and PLCd (84 kDa), stimulated by
transglutaminase-II.29 All three types are expressed in
cardiomyocytes.
Regulation of adrenergic receptor signalling
The b2-AR is the most thoroughly studied with regard to
signalling. Four paradigms have been delineated from
studies of co-expression of wild-type and mutated b2-AR
with various combinations of G-proteins in different in vitro
cell systems. One assumes that these regulatory mechanisms
also apply to the other GPCRs in different tissues.
(i) Upon agonist activation, the b2-AR couples to the G-
protein heterotrimer, mainly with its third intracellular loop
between the transmembrane helices TM5 and TM6 and part
of the intracellular C-terminus immediately following the
TM6. It couples preferentially to Gas forming a stoichio-
metric 1:1 complex. However, the b2-AR may instead also
couple to Gai or Gaq, activating their corresponding
signalling pathways (Fig. 1). The G-protein speci®city is, at
least in part, determined by the type of agonist.94 This
Fig 3 Interrelation of adrenergic and calcium signalling pathways affecting inotropy (contractility) and lusitropy (relaxation) in the
cardiomyocyte.7 14 21 25 42 45 82 98 AC=adenylyl cyclase; AR=adrenergic receptor; CaM=calmodulin; CaMKs=calmodulin-dependent kinases;
cAMP=cyclic AMP; cTnC, cTnI=Ca2+-binding and inhibitory troponin subunits respectively; DAG=diacylglycerol; DHPR=dihydropyridine receptor
(L-type Ca2+-channel); FKBP=FK506-binding regulatory protein; Gi, Gs, Gq, Gbg=G-protein subunits; GRK=G-protein-coupled receptor kinase;
IP3=inositol trisphosphate; IP3R=IP3 receptor (SR Ca2+ release channel); MRLC=myosin regulatory light chain; PDE=phosphodiesterase; PKA,
PKC=target-speci®c serine±threonine protein kinases; PLC=phospholipase C; PLN=phospholamban; PMCA=sarcolemmal Ca2+ pump; RyR=ryanodine
binding receptor (SR Ca2+ release channel); SERCA=SR Ca2+ pump; SR=sarcoplasmic reticulum.
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implies that the agonist-induced conformation of the
receptor favours the type of G-protein with which it
interacts. For instance, salbutamol and ephedrine display a
much higher ef®cacy with Gaq than Gas or Gai. On the
other hand, isoproterenol is more effective than salbutamol
with Gai. It was recently shown that the selective b2-AR
antagonist ICI-118,551 exerts a direct negative inotropic
effect by acting as a b2-AR agonist, directing it away from
coupling to Gas towards coupling to Gai.28 Furthermore,
upon stimulation by catecholamines the b2-AR interacts
much faster with Gas than with Gai and Gaq. This could
generate intracellular signals in a timely, ordered fashion. In
general, AR signalling is terminated by phosphorylation at
multiple sites in the third intracellular loop and in the
C-terminal region. However, PKA-dependent phosphoryl-
ation in the third loop (serines 261 and 262) and in the
proximal C-terminal region (serines 345 and 346) of the
b2-AR switches its predominant coupling from the stimu-
latory Gas to the inhibitory Gai, thereby inhibiting the AC
and promoting activation of the mitogen activated protein
kinase (MAPK) signalling cascade (see next section).12 97
(ii) Signal termination is commonly referred to as
desensitization, i.e. attenuation of receptor signalling des-
pite the continued presence of a stimulus. Desensitization
may occur under physiological or pharmacological stimuli
as well as under pathological conditions.12 54 72
Homologous desensitization involves phosphorylation of
two adjacent serines (355 and 356) in the C-terminal region
of the b2-AR by a family of G-protein-coupled receptor
kinases (GRKs), whose activation does not require the
production of second messengers. The six different GRK
isoforms are tissue-speci®c. GRK2 and GRK5 (formerly
referred to as b-ARKs; 68 and 80 kDa respectively) are
expressed in cardiomyocytes and display speci®city for
agonist-activated receptors; non-activated receptors or
antagonist-bound receptors are usually not phosphorylated
by GRKs. In contrast to b1- and b2-AR, the b3-AR lacks
phosphorylation sites and is refractory to desensitization by
GRKs or PKA. The Gbg subunits seem to play a role in
recruiting the cytoplasmic GRKs to the membrane envir-
onment of their receptor substrates and the membrane
phospholipids required for kinase activation.12 54
Heterologous desensitization occurs in the absence of
agonist occupancy and is regulated by the signalling of
another receptor via an intermediary second messenger.
Induction of cAMP by receptor signalling leads to phos-
phorylation of several intracellular serines of the b2-AR by
cAMP-dependent PKA. Thus, phosphorylation by PKA
turns off signalling through the receptor's normal partner
Gas and, at the same time, facilitates receptor coupling to
the inhibitory Gai.12 21 97 Stimulation of PKC via the PLC±
PIP2±DAG pathway also leads to phosphorylation of the
receptor and its heterologous desensitization.
Desensitization is an acute response involving binding of
arrestin to the phosphorylated C-terminus of the b2-AR.
Arrestin, together with the heterotetrameric adapter com-
plex AP2, delivers the receptor to clathrin-coated pits for
endocytosis to endosomes or to lysosomes. In the endo-
somes the b2-AR is dephosphorylated by speci®c protein
phosphatases. This resensitized receptor then recycles back
to the cell membrane. However, fusion of the endosome
with lysosomes leads to b2-AR degradation. Desensitization
is not always coupled to internalization but exhibits receptor
type-speci®city. For instance, under agonist stimulation
50±80% of the b2-AR internalizes within a few minutes,
whereas the b1-AR does not internalize but remains at the
cell surface, even in the desensitized state. The different
a-ARs internalize only moderately, except for the a2A-AR,
which remains at the membrane. In contrast to desensitiza-
tion, downregulation denotes a chronic process, during
which agonist overstimulation promotes increased receptor
degradation concomitant with a reduced de novo synthesis
rate that does not match the loss of receptors.12 71
(iii) Recent reports on homo- and heterodimerization
between receptor subtypes suggest a potential concentration
of receptor complexity that could account for previously
unexpected pharmacological diversity.3 a2-AR and b2-AR
may form homodimers. The b2-AR was found to form
dimers on agonist activation, and the agonist-induced
homodimer seems to represent the active b2-AR species.
Dimerization is established between the sixth and seventh
transmembrane domains of the two receptors involved.78
Heterodimers have been found between the a2A-AR and
b1-AR, the b1-AR and b2-AR, and the a2C and M3-
muscarinic receptors, as well as between the b2-AR and
d-opioid receptors.3 Formation of the b1-AR and b2-AR
heterodimer inhibits the agonist-promoted internalization of
the b2-AR and its ability to activate the MAPK cascade46
(see next section).
(iv) A GPCR-associated protein may directly mediate
signalling, as in the case of the G-proteins themselves.
Alternatively, a GPCR-associated protein may regulate
receptor signalling by controlling receptor localization and/
or traf®cking, e.g. by internalization. Finally, a GPCR-
associated protein may act as a scaffold, physically linking
the receptor to various effectors. Scaffold proteins are
de®ned as proteins that associate with two or more partners
to enhance the ef®ciency and/or speci®city of cellular
signalling pathways. The family of PKA-anchoring proteins
(AKAPs) was one of the ®rst to be recognized as scaffold
proteins.30 85 87 Two AKAPs, AKAP250, also known as
gravin, and AKAP79, were found to interact with the
C-terminus of the b2-AR.
Relation of adrenergic to global
cardiomyocyte signalling
The G-protein-stimulated signal pathways continue via
distinct classes of protein serine±threonine kinases (PKA,
PKB, PKC, PKG), which speci®cally phosphorylate serine
and threonine residues in their target proteins.13 60 61 76 85 87 99
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PKA and PKC are the key players in the adrenergic signal
relay system. In the absence of cAMP, PKA is an
enzymatically inactive tetrameric holoenzyme consisting
of two catalytic subunits (PKAC monomer, 40.4 kDa)
bound to a regulatory subunit dimer (PKAR monomer, 42.5
kDa). cAMP binds cooperatively to two sites on each PKAR
subunit. Upon binding of four molecules of cAMP, the
enzyme dissociates into a PKAR dimer with four molecules
of cAMP bound, and two free, active PKACs. The PKC
exists in a variety of isoforms with functional speci®cities.
There are 10 mammalian PKC isoforms, ranging in
molecular weight from 68 to 102 kDa. The four conven-
tional PKCs (a, b1 with a splice variant b2, and g) require
Ca2+ and DAG for activation; the four novel PKCs (d, e, h/L
and q) are Ca2+-independent but require DAG for acti-
vation; ®nally, the two atypical PKCs (z and l) lack both the
Ca2+ and the DAG binding domain.
G-proteins are also able to activate the monomeric
GTPase Ras via different phosphorelay systems. Ras
represents a master switch in transferring extracellular
signals for growth and differentiation via the four MAPK
cascades to the nucleus (Fig. 2).33 37 53 55 64 Among these
four cascades, (i) ERKs (extracellular signal-regulated
kinases) are activated by growth factors and regulate
cardiac hypertrophy and apoptosis, (ii) the more recently
characterized big MAP kinase-1 (BMK1, also called ERK5)
pathway transmits oxidative stress signals to the cell
nucleus, (iii) the four p38 MAPK isoforms (a, b, g and d)
are activated by cytokines and environmental stress and are
also involved in regulation of apoptosis, and (iv) the JNKs
(c-Jun N-terminal kinases) are critical regulators of tran-
scription. Speci®city of AR subtype signalling may be
achieved by proteins that do not have intrinsic catalytic
activity but serve as adapter and anchoring proteins. By
keeping the reaction partners of a particular signalling
pathway in close proximity to the effector site, they form
so-called signalling modules. Such a signalling module of
activated PKCe with ERK has been demonstrated to be
operative in mitochondria, where it induces cardioprotec-
tion.5 Another recent example is the conserved sequential
MAPK cascade Raf±MEK±ERK, in which the two upstream
kinases of the module, Raf and MEK, remain cytoplasmic.
In resting cells, ERK is anchored to MEK, whereas upon
activation it rapidly detaches and translocates to the
nucleus.73 A similarly complex signalling network with
redundancies, as revealed between the downstream signal-
ling pathways of ARs (Fig. 1), can also be discerned among
the MAPK cascades (Fig. 2).
Calcium as a signal transmitter
Calcium is highly toxic for any cell, yet it represents the
major intracellular messenger regulating most activities,
including contractility, metabolism, transport, secretion and
transcription. The Ca2+ signal varies in its character
depending on the circumstances. One may see a long-
lasting cytoplasmic increase in Ca2+ concentration activat-
ing metabolism as well as gene expression, or short-lasting
(50±200 ms) Ca2+ transients triggering contraction.7 8 14
Calcium signalling for different cellular responses and its
consequent requirement for energy production depend on
the strictly maintained intracellular Ca2+ homeostasis,
which is largely monitored by adrenergic signalling path-
ways (Fig. 3). The heart makes up less than 0.5% of the
body mass, yet it consumes around 11% of the total energy
expenditure. The complex scheme in Fig. 3 comprises the
explicitly reported interconnections between the intra-
cellular adrenergic and Ca2+ signalling pathways, but in
reality probably many more may exist. In the resting
myocyte the cytoplasmic Ca2+ concentration is below 10±7
M and increases transiently by almost two orders of
magnitude upon stimulation by the action potential (AP).
The Ca2+ concentration in the mitochondrial matrix follows
closely that of the cytoplasm, involving the regulation of
metabolic key enzymes of the tricarboxylic acid cycle.14 99
Several ATP-consuming ion pumps and electrogenically
driven ion exchangers are responsible for ensuring a
suf®ciently low cytoplasmic Ca2+ concentration during
diastole. In diastole, the cytoplasmic Ca2+ concentration
must be signi®cantly lower than what is found in ultrapure
bidistilled water after passage through an ion exchange
resin, as it is used in the laboratory. Any cell damage which
impairs the tight control over the cytoplasmic Ca2+
concentration leads to abnormal energy metabolism in the
mitochondria and ends in cell death.
In contrast to the low cytoplasmic Ca2+ during rest, the
Ca2+ concentration outside the myocyte ranges between 1
and 2 mM, thus establishing a gradient of over 10 000-fold.
This outside±inside gradient enables the Ca2+ ion to
function as a signal, provided there are suf®ciently sensitive
Ca2+-binding signalling components in the cell.27 Inside the
cardiomyocytes, the Ca2+ signal is conveyed to the target
sites by the Ca2+-sensing proteins troponin-C (TnC) and
calmodulin (CaM), which reversibly bind Ca2+ ions with
af®nities in the range of 10±5 to 10±6 M. These Ca2+
af®nities are just in the range attained by Ca2+ signalling
transients, taking into account the intracellular presence of
around 1 mM Mg2+ ions, which are competing for the Ca2+
binding sites with an af®nity 104 times lower than that of
Ca2+. Some Ca2+-regulated targets have their own Ca2+
binding sites and are not dependent on TnC or CaM as an
intermediate signal component.
Calcium enters the cardiomyocyte down the concentra-
tion gradient via the high voltage-activated (opening at
around ±20 mV) L-type Ca2+-channels of the sarcolemma
(particularly accumulated in the transverse T-tubules) as
often as an AP stimulates the cell. The low voltage-activated
(opening between ±60 and ±40 mV) T-type channels are not
concentrated in the T-tubules and contribute little to the
Ca2+ entry from outside.6 18 34 41 They are primarily found
in secretory and smooth muscle cells and in the cardiac
nodal cells, where they are involved in rhythm control. The
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L- and T-type channels belong to a family of cell surface
Ca2+-channels composed of four subunits in a 1:1
stoichiometry (a1, a2, b, d). The human a1C (Cav1.2)
subunit (2221 amino acids, 249 kDa), occurring in heart
(Cav1.2a) and smooth muscle (Cav1.2b sharing 93%
homology), contains four domains with six transmembrane
helices each (S1±S6, yielding a total of 12 transmembrane
helices). The S6s of each domain together form the Ca2+
pore. The four transmembrane S4 helices of 19 amino acids
each contain positively charged residues at every third
position, together forming the voltage sensor of the pore.
The P-loop between the transmembrane helices S5 and S6 is
very much conserved among the different Ca2+-channels
and provides the ®lter selectivity for Ca2+. The b-subunit
associates with the a-subunit at the inner side of the
membrane and determines the kinetics of the channel
activities (opening, closing, inactivation). The b2-subunit
(73.5 kDa) is characteristic of the heart while the b3-subunit
(54.5 kDa) is more typical of smooth muscle. The Cav1.2
channel activity is enhanced by phosphorylation by PKA,
PKC and CaMK, but is inhibited by Ca2+ when its
cytoplasmic concentration is increased during sustained
cell activity (negative feedback control).34 39 41 93 Calcium
binds directly to the C-terminal intracellular part of the
Cav1.2, which contains a Ca2+-binding EF-hand domain
(see below), but nearby is also a binding site for CaM, which
contributes to sensing Ca2+ signalling. For prolonged
elevation of cytoplasmic Ca2+, ill-de®ned ligand-gated
channels (also called store-operated channels) are thought
to be involved in Ca2+ entry after the Ca2+ release from
internal stores.14 22
For excitation±contraction coupling, Ca2+ is primarily
released from intracellular stores in response to extracellular
stimuli (Fig. 3). The endoplasmic reticulum (ER) in non-
muscle cells and its derivative, the SR in striated muscles
(cardiac and skeletal) as well as in smooth muscle, are able
to accumulate Ca2+ up to a concentration of 30 mM and to
store it bound to proteins with multiple low-af®nity Ca2+-
binding sites, such as calsequestrin and calreticulin.
Calsequestrin (46.4 kDa) is found in cardiac and skeletal
SR while calreticulin (45.0 kDa) is mainly present in the SR
of smooth muscle and ER of non-muscle cells. Both the SR
and ER contain two ligand-gated Ca2+ release channels, the
ryanodine binding receptor (RYR) and the IP3 binding
receptor (IP3R). The Ca2+ entering the cell on stimulation
induces a far larger (5- to 20-fold) release of Ca2+ from the
closely positioned intracellular SR into the cytoplasm via
the RYR, a process called Ca2+-induced Ca2+ release
(CICR).7 14 16
The RYR channel forms a tetramer with four equal
subunits of 565 kDa each, which combine with four
regulatory proteins, called FKBP12.6. FKBP, with a mass
of 12.6 kDa belongs to the group of cyclophilins, which
accelerate protein folding, acting as peptidyl-prolyl cis-
trans isomerases or rotamases. They are inhibited by the
immunosuppressor drugs FK506 (tacrolimus) and rapamy-
cin (sirolimus), but not by cyclosporin A. Of the three
isoforms, RYR1 (with a total molecular weight of around
2300 kDa) occurs in skeletal muscle, RYR2 in cardiomyo-
cytes and RYR3 in non-muscle cells.49 88 In addition, the
RYR2 serves as scaffold protein, combining with numerous
key regulatory components in the junctional SR complex,
including CaM, PKA, type-1 and type-2 phosphatases and,
at the luminal SR surface, triadin and calsequestrin.
Calcium can also be released from the SR via the IP3R
channel, which is composed of four equal subunits of 313
kDa each. The IP3R channel also exists in three isoforms,
with IP3R2 in cardiomyocytes. The IP3R2 is activated by
IP3 produced by PLC. The rate and extent of Ca2+ liberation
by IP3 is much lower than for CICR via the RYR2, and thus
hardly contributes to excitation±contraction coupling in
cardiomyocytes. However, intracellular Ca2+ release by IP3
is important in the slow motion of smooth muscle contrac-
tion and in ®ne-tuning the activity of atrial myocytes, where
the SR has more IP3R2 than in the ventricular myocytes.
RYR2 and IP3R2 share structural and functional similarities
and have some sequence similarity in their C-terminal
domains, although the latter is about half the size of the
former.77 The two Ca2+ release channel types interact and
are inhibited by high Ca2+ and CaM, but become activated
by phosphorylation by PKA, PKC or a Ca2+-CaM-depend-
ent protein kinase-II (CaMK-II) (Fig. 3). Phosphorylation of
RYR2 induces dissociation of the FKBP regulatory protein,
which inhibits the RYR2 channel when bound to it.
Intracellular calcium handling in
cardiomyocytes
Cardiomyocyte contraction and cell activity in general are
terminated by removing Ca2+ from its regulatory sites on
TnC, CaM and other proteins. This is achieved by quickly
and ef®ciently lowering the cytoplasmic Ca2+
concentration.8 14 27 45 Two proteins are involved in
moving Ca2+ out of the myocyte, the sarcolemmal Ca2+
pump (PMCA) and the Na+/Ca2+-exchanger (or antiporter,
NCX1), and one in taking it up into the intracellular store
(the Ca2+ pump of the SR, SERCA2a) (Fig. 3). The
immediate removal of Ca2+ from the regulatory sites is
effected by the SERCA2a pump, which has high af®nity but
low transport capacity. The NCX1 extrudes Ca2+ out of the
cell during diastole with relatively low af®nity but high
transport capacity, thus ensuring a suf®ciently low Ca2+
concentration during cell rest. While the NCX1 couples the
outward transport of one Ca2+ to the entry of three Na+
down its outside±inside gradient, the SR and the sarcolem-
mal Ca2+ pumps depend on ATP consumption. The outside±
inside Na+ gradient (established by the Na+/K+ pump, which
also uses ATP) allows the electrogenically driven exchange
of Ca2+ against Na+ by the NCX1. Stimulation of the Na+/
K+ pump by phosphorylation by PKA and/or PKC is under
the control of the ARs, in particular the b1-AR (Figs 2 and
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3). In mice and rats, about 92% of the Ca2+ ions are pumped
back into the SR by the SERCA2a and only 7% are extruded
out of the cell by the NCX1. In larger mammals, such as
rabbits, cats, dogs and humans, SERCA2a and NCX1 are
able to lower the Ca2+ concentration to about 70 and 28%
respectively. The slow sarcolemmal PMCA pump con-
tributes little (1±2%) to the process of lowering the
cytoplasmic Ca2+ concentrations in the heart, whereas its
function is decisive for Ca2+ homeostasis in smooth and
non-muscle cells.
The amount of AP-induced Ca2+ entry is primarily
dictated by the duration of the AP and the open probability
of the L-type Ca2+-channel. The Ca2+ extruded after the
heart-beat must match the amount of Ca2+ that enters just
before the beat, otherwise the cell would not be in
steady state but would either lose or gain Ca2+. This
provides a quantitative framework for the dynamic Ca2+
¯uxes in the cardiomyocytes. The SERCA2a pump is one of
the main players in terminating contraction and restoring
resting cytoplasmic Ca2+ concentrations. It is known that
during heart failure in humans, as well as in a rabbit model,
the functional expression of SERCA2a is reduced and
NCX1 is increased.8 32 This results in a loss of SR Ca2+
concomitant with enhanced Ca2+ extrusion, leading to a net
loss of intracellular Ca2+. Consequently, less Ca2+ is
available in the SR for the subsequent heart-beats, which
is the central cause of systolic contractile de®cit in heart
failure.
The NCX1 (splice variant NCX1.1) is the cardiac isoform
with 938 amino acids (104 kDa), whereas the NCX2 is
preferentially expressed in the brain and NCX3 in skeletal
muscle.62 70 82 100 Its topology is not yet clear, suggesting
either 11 or nine transmembrane helices. Interestingly, the
NCX1 may function in reverse mode during the plateau of
the AP (Ca2+ in¯ux coupled with Na+ out¯ux). This may be
of physiological signi®cance as the NCX1, like the L-type
Ca2+-channel, is concentrated in the transverse T-tubular
system and may be able to elicit Ca2+-induced Ca2+ release
via the RYR2 from the SR. This would reinforce the Ca2+
release process from the RYR2 ascribed to the interaction of
the L-type Ca2+-channel with the RYR2 (as mentioned
above). The NCX1 can be phosphorylated and stimulated by
both PKA and PKC, and is therefore under the control of
ARs. PMCA and SERCA belong to a subfamily of the P-
type ATPases. The sarcolemmal Ca2+ pump (PMCA)
transports one Ca2+ per ATP out of the cell, while
SERCA2a takes two Ca2+ per ATP up into the SR. From
the isoforms of the four genes giving rise to PMCA1-
PMCA4 and over 20 splice variants, PMCA1c (1249 amino
acids, 138 kDa, with 10 putative transmembrane helices)
seems to be the main cardiac species, but other isoforms are
also expressed in cardiomyocytes. PMCA activity depends
on binding CaM, and may be further stimulated by
phosphorylation via PKA and/or PKC (Fig. 3).
The cardiac SR Ca2+ pump SERCA2a, together with its
regulatory protein phospholamban (PLN), is the most
important component linking adrenergic control to inotropy
and rhythmicity.4 8 14 22 48 Three genes were identi®ed for
the SR Ca2+ pump, SERCA1, SERCA2 and SERCA3,
which are spliced into several isoforms. SERCA1a is mainly
expressed in fast skeletal muscle, while SERCA1b is
abundant in fetal and neonatal tissues. The SERCA2 gene
encodes four splice variants: SERCA2a, expressed in the
heart and in slow skeletal muscle, SERCA2b, expressed in
smooth muscle and with variants (types 2 and 3) in non-
muscle cells and (type 4) in neuronal cells. The recently
solved crystal structure of the SERCA1a pump in the Ca2+-
bound state reveals (besides the 10 transmembrane helices)
three large cytoplasmic domain structures constituting the
nucleotide binding site, the catalytic site and the phos-
phorylation site.91 The cardiac SERCA2a is 997 amino
acids long (110 kDa) and is under the direct control of a
CaM-dependent kinase-II (CaMK-II), which enhances its
transport capacity by phosphorylation of Ser38. The major
regulator of SERCA2a, however, is PLN, with 52 amino
acids (6.1 kDa) and one transmembrane helix (C-terminal
amino acids 32±52). It is predominantly expressed in
ventricular cardiac muscle, but also in small amounts in
slow-twitch skeletal muscle, smooth muscle and endothelial
cells. As a monomer, it associates with and ef®ciently
inhibits the SERCA2a pump, by interaction of its trans-
membrane helix with helices of the pump and its
cytoplasmic domain with the cytoplasmic domain of the
pump. Its inhibitory effect is delicately regulated by
phosphorylation induced by different signalling pathways.
The cytoplasmic domain is amenable to regulation by
phosphorylation of Ser16 by PKA, Thr17 by CaMK-II, and
Ser10 by PKC (Fig. 3). Phosphorylation to various degrees
causes gradual dissociation of PLN from SERCA2a,
relieving the inhibition of the Ca2+ pump and thus
increasing the rate of relaxation (lusitropic effect). When
not associated with SERCA2a, PLN polymerizes into
pentamers.
To further increase the complexity, sarcolipin (SLN),
which is a homologue of PLN with 31 amino acids (3.8
kDa), forming just one transmembrane helix and lacking
most of the cytoplasmic portion present in PLN, was
discovered recently.4 48 It is highly expressed in human fast-
twitch skeletal muscle and in small amounts predominantly
in atrial muscle. SLN inhibits the SERCA1a (fast skeletal
muscle) and SERCA2a (cardiomyocytes) by lowering the
Ca2+-binding af®nity and slowing the ATPase turnover rate.
In addition, SLN is able to induce a superinhibitory effect
apparently by binding to PLN and thus preventing PLN
from polymerizing into pentamers. A small amount of SLN
may be suf®ciently potent to shift the equilibrium of
pentameric PLN towards the monomer, inhibiting
SERCA2a. In view of the decisive power of the SR-
SERCA2a pump in regulating contractility, both SERCA2a
and PLN represent potential targets for new therapeutic
approaches.
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Adrenergic ®ne-tuning of contractility
TnC and CaM are the main transmitters of the intracellular
Ca2+ signal. Both belong to the EF-hand protein super-
family, which contains 66 distinct subfamilies with a total of
almost 600 known proteins.59 The characteristic EF-hand,
with 30 amino acids, consists of a ¯exible loop (eight amino
acids) with ®ve residues, providing oxygen for reversibly
complexing with Ca2+, which is ¯anked on both sides by a
short a-helix of approximately 11 amino acids. Reversible
binding of Ca2+ to the loop induces a conformational change
that moves the two rigid helices relative to one another, and
this movement is transmitted to the associated target
proteins. Both TnC and CaM contain four such Ca2+-
binding domains, which have arisen from a common single
Ca2+ binding ancestor protein by several steps of gene
duplication and fusion. The expression of TnC is restricted
to striated muscles (skeletal and cardiac), where it regulates
contraction and is located in the heterotrimeric troponin
complex on the actin ®lament in the sarcomeres. This
complex consists, besides TnC, of troponin-I (inhibitory
component, TnI) and troponin-T (tropomyosin binding
component, TnT).51 66 67 TnC contains either two ions or
two ions bound to the two C-terminal binding sites for
protein stabilization, whereas in the fast skeletal muscle
isoform (159 amino acids, 18.0 kDa) the two N-terminal
sites reversibly bind signalling Ca2+.27 59 79 In the cardiac
TnC (TnC) isoform (161 amino acids, 18.4 kDa) only one of
the two N-terminal binding sites is functional for regulation.
Binding of Ca2+ to the regulatory site of cTnC modulates its
interaction with TnI and, as a consequence, it also affects
the interaction of TnI with TnT and tropomyosin. In the
absence of Ca2+, TnI inhibits the interaction of myosin-II
with actin (relaxation). Binding of Ca2+ to cTnC relieves the
inhibitory effect of TnI, and contraction ensues. The
troponin complex is positioned along the actin ®lament at
every seventh actin monomer, and the Ca2+-induced
conformational changes of TnC are imparted to all actin
monomers via TnI and TnT (around 32 kDa) acting through
the two tropomyosin threads that run on both sides along the
entire actin ®lament (Fig. 4). Tropomyosin is an elongated
dimeric protein about 40 nm long, comprising two a-helical
subunits (284 amino acids each, 32.8 kDa) arranged in
parallel orientation. The tropomyosin molecules are strung
together head-to-tail, thus forming threads along the actin
®laments with a length of 600±1000 nm. Cardiac TnI (210
amino acids, 24.0 kDa) is somewhat larger than its skeletal
muscle counterparts and includes a unique 32-residue
N-terminal extension with two adjacent residues, Ser23
and Ser24, that can be phosphorylated by either PKA or
PKC. TnI phosphorylation under the control of distinct AR
subtypes (Fig. 3) lowers the af®nity of TnC for calcium ions.
Calcium then more readily dissociates from TnC at the end
of systole, thus enhancing relaxation (lusitropic effect).
In contrast to TnC, CaM (148 amino acids, 16.7 kDa) is an
ubiquitously expressed Ca2+ signalling protein found in all
eukaryotic cells. Its amino acid sequence is identical in the
human, rat, mouse, rabbit, chicken, frog, sea urchin and
torpedo ®sh.59 77 This makes it one of the most highly
conserved proteins known. With four Ca2+ bound, it
regulates over 40 enzymes, channels and structural proteins.
In the so-called apo form, the Ca2+ binding sites are empty or
may be occupied by Mg2+. It operates by (i) reversible
binding to the target protein when Ca2+ is bound, (ii)
remaining combined with some proteins in both apo and
Ca2+-bound form, as in the heteromeric phosphorylase
complex, or (iii) forming part of the target protein structure
as heterochimera, the gene encoding EF-hands being fused
to the gene of the target protein. While Ca2+-CaM interacts
with PMCA, L-type Ca2+-channel and RYR2 (as mentioned
above) for direct regulation, most of its regulatory activities
are mediated by CaM-dependent kinases (CaMKs) and
subsequent phosphorylation reactions (Fig. 3). CaMKs are
activated by phosphorylation, like most protein kinases,
either by autophosphorylation triggered by binding of CaM
or by another CaM-dependent kinase, called CaMK kinase
(CaMKK). The role of this CaMKK is reminiscent of that of
MAP kinase kinase (MAPKK) in the MAP kinase cascade
(Fig. 2).38 44 Several types of CaMK are multisubstrate
kinases that phosphorylate different target proteins, while
others are speci®c for one particular protein; for instance, the
myosin light chain kinase (MLCK). The multisubstrate
CaMK-II is a multimeric enzyme composed of up to 12
subunits, whereas the skeletal and cardiac muscle MLCK
(65 kDa) is monomeric. The MLCK phosphorylates speci®c-
ally the regulatory light-chain subunit (RLC) of cardiac
myosin-II at Ser14, rendering the contractile apparatus more
sensitive to the Ca2+ trigger (positive inotropy). The same can
also be achieved by RLC phosphorylation by PKC (Fig. 3).
Fig 4 Scheme of sarcomeric contractile and regulatory proteins. M=pairs
of myosin heads forming the contractile crossbridges (myosin tails are
black); ELC=essential myosin light chains; RLC=regulatory myosin light
chains; TnC, TnI, TnT=troponin components associated with the
tropomyosin threads. Upon binding of Ca2+ to TnC, the troponin
complex moves the tropomyosin threads deeper into the groves along the
actin ®lament so that the myosin heads can attach to the actin monomers
and contract. In the absence of Ca2+ the tropomyosin threads prevent the
myosin heads from attaching to actin (relaxation, steric blocking
model).51 57 79
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Frank±Starling and negative feedback
mechanisms
Physiological contraction generates both isometric force
(ventricular pressure) and rapid shortening to eject the
blood. As discussed above, there are two main ways to
change the strength of contraction: by altering the amplitude
and/or duration of the Ca2+ transient, and by altering the
sensitivity of the contractile ®laments to Ca2+ (by phos-
phorylation of the myosin RLC and/or TnI). Calcium-
sensitivity also increases by mechanical stretching as the
heart ®lls with blood, resulting in stronger subsequent
contraction.23 This is due to the compression of the
transverse ®lament lattice that occurs on stretching and
brings the contractile ®laments in the sarcomeres closer
together. This facilitates actin±myosin interaction and
increases the af®nity of TnC for Ca2+. It represents an
important autoregulatory mechanism by which the heart
adjusts to increased diastolic ®lling, and is called the Frank±
Starling response.
In general, the positive inotropic and lusitropic effects are
mainly elicited by b1- and b2-AR stimulation and mediated
through cAMP-dependent PKA phosphorylation of PLN,
TnI, the L-type Ca2+-channel and RYR2. The degree of
positive inotropy is directly related to the amount of cellular
Ca2+, which steadily increases with time under these
conditions. Without safety precautions, it would end in
cardiac arrest in systolic contracture. This is, however,
normally not observed (except with digitalis glycoside
overdoses), as the cardiac phosphodiesterase (PDE)
isoforms degrade cAMP, thus keeping the overall b1-AR
stimulation at bay. At least four types of PDE isoforms
(PDE1±PDE4, varying in size from 61 to 124 kDa), with
over 20 splice variants, most of them membrane-associated,
have been identi®ed in cardiomyocytes.25 35 52 83 Via cyclic
nucleotide metabolism, PDEs are also involved in the
regulation of the L-type Ca2+-channels. The activity of
PDE1 depends on the association of the four Ca2+ bound
form of CaM, which increases concomitantly with the
increase in cytoplasmic Ca2+; PDE2 is stimulated by cAMP;
PDE3 is inhibited by cAMP; and PDE4 is insensitive to
cAMP. The PDEs are operative as homodimers and
contribute decisively to the contractile responsiveness.
The fact that PDE activity reduces inotropy by degradation
of cAMP prompted the development of PDE inhibitors, such
as amrinone, milrinone and enoximone (bipyridines inhibit
PDE enzymes, as do methylxanthines), which are in clinical
use for the acute treatment of congestive heart failure.
Despite its complexity, the PDE system provides a powerful
negative feedback control system of great physiological
signi®cance (Fig. 3).
In conclusion, although Ca2+ is traditionally described as
a second messenger that is liberated from intracellular stores
(SR), Ca2+ entering the cell may activate a number of
processes acting directly as a ®rst messenger.14 In particu-
lar, it ampli®es its own signalling capacity by the Ca2+-
induced Ca2+ release from the SR via the RYR2, thus also
acting as a second messenger. Furthermore, the second
messenger IP3, liberated by PLC from PIP2 (as mentioned
above), provokes the release of Ca2+ via the IP3R of the SR,
acting then as a third messenger. In addition, adrenergic
signalling pathways exert their effects (balancing between
positive or negative inotropy and lusitropy) almost exclu-
sively by modulating cytoplasmic Ca2+ concentrations and
signalling transients in amplitude and frequency, thus
adding yet another step to the Ca2+ signalling cascade.
Consequently, Ca2+ may well be viewed as operating at the
same time as a ®rst, second and third messenger. In the
healthy heart, the combined signalling circuits coordinate
contractility and energy production in a concerted way. The
cellular and molecular basis explains how adrenergic
stimulation induces positive inotropy together with positive
lusitropy (faster relaxation) under increased haemodynamic
load. This combination of stronger but shorter contraction
twitches makes it possible to accommodate more beats per
time interval, thus increasing cardiac output under increased
workload. However, upon transition from compensated
haemodynamics to overt heart failure or during ischaemia/
reperfusion injuries, the integrated signalling network may
become unbalanced and dysfunctional, eventually ending in
collapse.32 49 71 79 99
Adrenergic regulation of heart rate
Maintaining adequate perfusion of vital organs is the main
task of the myocardium. Adaptation to increased workload
is effected by coordination of two principal mechanisms,
which both are under sympathetic and parasympathetic
control: (i) positive inotropy as described above, and (ii)
increase in heart rate. Recently a voltage-gated cation
channel family was cloned comprising four members:
HCN1±HCN4, in the 89±129 kDa range.9 40 56 HCN
channels open upon hyperpolarization and close at positive
potentials. cAMP and cGMP increase channel activity by
shifting the activation curve of the channels to more positive
voltages. The stimulatory effect of cyclic nucleotides is not
dependent on protein phosphorylation but is due to a direct
interaction with the HCN channel protein. HCN channels
contain six transmembrane helices (S1±S6) and are believed
to assemble in tetramers. The S4 segment is positively
charged and serves as voltage sensor. The C-terminal region
of all HCN channels contains a cyclic nucleotide binding
domain that confers regulation. The channels are activated
during membrane hyperpolarization after the termination of
an action potential and provide an inward Na+ current that
slowly depolarizes the plasma membrane. Sodium perme-
ates the channels ®ve times more readily than K+. HCN
channels are found in neurons and heart cells. HCN4
represents the predominant species in the sino-atrial node
(SAN) controlling heart rate and rhythm. HCN2 is the most
abundant neuronal channel and is found almost ubiquitously
in the brain. Sympathetic stimulation of the SAN raises
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cAMP concentrations, thus accelerating diastolic depolar-
ization and heart rate. Stimulation of muscarinic acetylcho-
line receptors slows the heart rate by the opposite action
(Fig. 1). Given the key role of HCN channels in cardiac
pacemaking, these channels represent promising pharma-
cological targets for the development of novel drugs for the
treatment of cardiac arrhythmias and ischaemic heart
disease.
Regulation of vascular smooth muscle
contraction
In cardiomyocytes, adrenergic signalling by b1- and b2-AR
causes robust positive inotropy. In contrast, the main b2-AR
signalling in bronchial and vascular smooth muscle cells
induces relaxation. This also applies to the contractility and
motility of non-muscle cells in general. Nevertheless, in
both cardiomyocytes and in smooth muscle cells the b-AR
signalling operates primarily via Gas±AC±cAMP±PKA
(Fig. 1). The difference resides in the regulatory mechanism
of the non-sarcomeric contractile apparatus, in which the
myosin-II and actin ®laments are not so regularly arranged
as in the sarcomeres of striated muscles. Smooth muscle
myosin-II is similar to its counterpart, consisting of two
heavy chains (HC, around 200 kDa) and two types of light
chains (in the 20 kDa molecular weight range). The
N-terminal portion of the HC folds into the globular myosin
head that forms the motor domain (Fig. 4).57 79 The two
myosin heads together form the crossbridge, which dis-
places the actin ®lament by cyclic interactions that convert
chemical energy obtained from the hydrolysis of ATP into
mechanical movement. The C-terminal half of the HC forms
an a-helix and the two helices of one molecule together
form a left-handed superhelix, called the myosin tail. The
myosin tails associate together and form the myosin
®lament. One essential light chain and one regulatory light
chain (RLC) are non-covalently associated with each
myosin head (Fig. 4). The enzyme kinetics and rates of
crossbridge movement are signi®cantly slower for smooth
muscle than for cardiac myosin-II.
The actin ®laments do not contain troponin, yet smooth
muscle contraction is still regulated by Ca2+, albeit in an
indirect way.38 50 57 86 The on±off switch for contraction
depends on the phosphorylation of smooth muscle myosin
RLC at Ser19 by the Ca2+-CaM-dependent smooth muscle
MLCK isoform and dephosphorylation by a myosin light
chain phosphatase (MLCP) (Fig. 5). The extent of RLC
phosphorylation determines shortening velocity and tension
development in smooth muscle. A second phosphorylation
of RLC at the adjacent Thr18 has only a small additional
positive effect on ATPase activity. Alternatively, the RLC
can also be phosphorylated by PKC, CaMK-II and other
protein kinases. In addition, contraction and relaxation of
smooth muscle may also be induced by hormones and cell
mediators, bypassing the canonical Ca2+ signalling path-
ways (see below).
The myosin RLC is the only known physiological
substrate for the MLCK.38 86 In vertebrates there are two
genes for MLCK. The skeletal muscle gene encodes a
kinase (65 kDa) containing a catalytic core and a regulatory
domain with an autoinhibitory and CaM binding sequence.
The smooth muscle gene expresses three transcripts in a
cell-speci®c manner because of alternate promoters and
splice variants, one with a molecular weight of 130 kDa, the
Fig 5 Regulation of contraction in smooth muscle and non-muscle
cells.10 15 17 31 38 41 50 57 75 81 84 86 89 95 AC=adenylyl cyclase;
AR=adrenergic receptor; BK=large-conductance Ca2+-activated
potassium channel; CaM=calmodulin; cAMP=cyclic AMP; CPI-
17=MLCP inhibitor; DAG=diacylglycerol; DHPR=dihydropyridine
receptor (L-type Ca2+-channel); GAP=GTPase-activating protein;
GDI=GDP dissociation inhibitor; GDP=guanosine diphosphate;
GEF=GTP exchange factor; GTP=guanosine triphosphate; ILK=integrin-
linked kinase; IP3=inositol trisphosphate; IP3R=IP3 receptor (SR Ca2+
release channel); MLCK=myosin light chain kinase; MLCP=myosin light
chain phosphatase; PKA, PKC=target-speci®c serine±threonine protein
kinases; PLC=phospholipase C; Rho=small monomeric GTPase;
RLC=myosin regulatory light chain; ROK=Rho-dependent kinase;
RyR=ryanodine binding receptor (SR Ca2+ release channel). Note that
MLCK requires Ca-CaM for activation (phosphorylation may inhibit
CaM binding), whereas MLCP is inactivated by phosphorylation of the
large myosin-targeting subunit.
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second with 210 kDa, and the third consisting of only the
C-terminal immunoglobulin-like domain of 17.5 kDa
(lacking the catalytic and regulatory domains), called
telokin. The short species (130 kDa) predominates in
smooth muscle while the long isoform (210 kDa) occurs
in many different non-muscle tissues and to a lesser extent
also in smooth muscle cells. Telokin is mainly found in
phasic smooth muscle tissues and may contribute to Ca2+
desensitization by cyclic nucleotides. The MLCK isoforms
of smooth and non-muscle tissues contain in their
N-terminal region several immunoglobulin-like domains,
one ®bronectin-like domain, and an actin-binding sequence,
all of which are not present in the skeletal muscle MLCK.
When Ca2+ binds to CaM, it associates with MLCK,
resulting in its activation and phosphorylation of the RLC
(Fig. 5). At this point, catecholamine signalling via b2-AR
is connected to the activation process of smooth muscle
contraction, allowing relaxation even in the presence of
activatory Ca2+ concentrations. Phosphorylation of MLCK
by cAMP-dependent PKA at the C-terminal Ser512 of the
CaM binding sequence lowers the af®nity for Ca2+-CaM
about 10-fold, thus resuming its inactive state by auto-
inhibition of its regulatory domain. Like the myosin RLC,
the MLCK can be phosphorylated by different kinases in
addition to PKA, such as PKC, CaMK-II and PAK (p21-
activated protein kinase) at various sites.
It was ®rst thought that regulation of smooth and non-
muscle contractility resides primarily in the activatory
process of RLC phosphorylation, followed by a more or less
constant rate of dephosphorylation by a constitutively active
MLCP (thought to represent a housekeeping enzyme). More
recently it was recognized that the MLCP also is regulated
by phosphorylation.84 86 MLCP is a holoenzyme consisting
of three subunits: a catalytic subunit of 37 kDa (PP1c), a
large myosin binding subunit (MBS) of around 130 kDa
(also known as myosin phosphatase targeting subunit,
MYPT), and a small 20 kDa subunit (M20) of unknown
function. The PP1c is a member of the type-1 protein
serine±threonine phosphatase family. The MBS exists in
two splice variants, M130 and M133. MBS binds
the relatively non-speci®c phosphatase PP1c near its
N-terminus and confers substrate speci®city by forming a
complex with myosin-II. MBS preferentially associated
with myosin-II when the RLC is phosphorylated and ready
for dephosphorylation. M20 binds to the N-terminal portion
of MBS. Inhibition of MLCP by phosphorylation at Thr655
in M130 (amino acid numbering for the human species) or
Thr696 in M133 by Rho-kinase-II (ROK-II) leads to
sustained vasoconstriction without concomitant lowering
of the cytoplasmic Ca2+ concentration (Fig. 5).
Phosphorylation of MBS induces dissociation from myo-
sin-II and from the catalytic PP1c subunit. Additional
phosphorylation sites for several different types of kinases
have also been shown for MBS in vitro, but their physio-
logical signi®cance has not yet been established.
Dephosphorylation of MBS proceeds slowly and does not
allow fast relaxation of the contractile apparatus.
However, another small molecular weight (16.7 kDa)
protein, CPI-17, is a potent reversible inhibitor of
MLCP.84 86 The inhibitory activity of CPI-17 is increased
more than 1000-fold by phosphorylation at Ser38 by PKC,
PKA, PKG or ROK, and also quickly reversed upon
dephosphorylation by the protein serine±threonine phos-
phatases PP2A, PP2B and PP2C, but not by type-1 protein
phosphatases. Consequently, CPI-17 is considered to act in
concert with myosin RLC phosphorylation by MLCK as the
on±off switch of smooth muscle contraction.
Phasic contraction and vascular tone
The Rho±ROK signalling pathway represents a sophisti-
cated device for ®ne-tuning vascular tone subject to a
variety of agonists, including noradrenaline, angiotensin-II,
endothelin, vasopressin, thrombin, prostanoids and many
others.75 84 86 89 95 All these agonists operate via Gaq-
coupled receptors that activate both Rho and PLC. The
PLC pathway, besides activation of PKC by DAG,
produces suf®cient IP3 to elicit a short-lasting Ca2+
transient by release of Ca2+ from the SR via the IP3R
channel (Fig. 5). This results in myosin RLC phosphoryl-
ation by MLCK and induction of a phasic contraction
followed by a long-lasting increase in tone. The Rho±ROK
pathway sets the tone of the contractile system by Ca2+-
independent mechanisms, preventing dephosphorylation
of the myosin RLC. However, this regulation is only
operative at a cytoplasmic Ca2+ concentration moderately
higher than during complete relaxation, maintaining partial
activation of the MLCK and a moderate degree of RLC
phosphorylation.
The Rho protein family comprises a group of small
monomeric GTPases (around 20 kDa) that function as
pivotal regulators in cell motility, cell proliferation and
apoptosis, involving the actin cytoskeleton and the micro-
tubule network. RhoA with bound GDP is kept in the
cytoplasm by association with GDI (GDP dissociation
inhibitor). The activity of RhoA is governed by the two
factors GEF (GTP exchange factor) and GAP (GTPase
activating protein). Agonist binding to surface receptors
induces the receptor-coupled Gaq to activate GEF, which in
turn promotes dissociation of GDI from RhoA and its
exchange of GDP for GTP (Fig. 5). RhoA with bound GTP
associates with ROK, releasing its autoinhibitory peptide
loop and the activated ROK then inhibits the MLCP by
phosphorylation of the MBS subunit. Subsequently, the
myosin RLC remains partially phosphorylated, maintaining
vascular tone. ROK is a protein serine±threonine kinase of
around 160 kDa with two isoforms: ROK-I (ROKb) and
ROK-II (ROKa). ROK-II is the main species in muscles and
brain. Besides the activation by RhoA, its activity can be
modulated further by autophosphorylation. In addition to
inhibition of the MLCP (by phosphorylation of MBS),
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ROK-II is also able to phosphorylate the myosin RLC and
thus contributes in two ways to the maintenance of vascular
tone.
Another mechanism contributing to the vascular tone is
the integrin-linked kinase system (Fig. 5).36 89 Integrins are
a family of cell adhesion receptors composed of an a-
subunit (several types of 140±210 kDa) and a b-subunit
(several types of 90±130 kDa), which are involved in
establishing cell-to-cell and cell-to-extracellular matrix
(ECM) contacts. Integrins are potential force-transduction
proteins because they span the surface membrane and link
the ECM to the underlying actin cytoskeleton in specialized
focal contact regions. Integrins activate signalling cascades
similar to those activated by growth factor receptors (Figs 1
and 2), but unlike these, integrins possess no intrinsic
tyrosine kinase activity and must therefore signal via
cytoplasmic kinases (Fig. 5). Such an integrin-linked
serine-threonine kinase (ILK) has recently been shown to
phosphorylate the MBS of MLCP, CPI-17, as well as the
myosin RLC in a Ca2+-independent manner. Induction of
Ca2+-independent contraction by RLC phosphorylation by
ILK becomes apparent only when the MLCP is inhibited.
Whether additional tyrosine kinases upstream of ILK are
involved in this signalling pathway is not known at present.
Further ®ne-tuning of smooth muscle contraction is
brought about by regulatory mechanisms at the actin
®laments.50 58 95 The regulatory protein caldesmon (93.3
kDa) is complexed to actin, tropomyosin and a Ca2+-binding
protein (CaBP). In the absence of Ca2+, caldesmon restricts
the interaction of the myosin heads with actin, but when
Ca2+ is bound to CaBP this inhibition is relieved. CaBP has
the same molecular weight as CaM (16.7 kDa) and is
believed to represent a covalently modi®ed form of CaM by
phosphorylation at Thr79 and Ser81. An additional basic
protein, calponin, of 33 kDa, predominantly found in
smooth muscle, binds to ®lamentous actin and CaM. Its
role is not clear yet, but it seems to be involved in
a1-agonist-induced signal transduction. In particular, it may
facilitate the PKC-ERK1/2 signalling pathway, leading to
phosphorylation of caldesmon, which also relieves the
actomyosin inhibition of the latter.
Intracellular calcium handling in smooth
muscle cells
Intracellular Ca2+ handling is as tightly controlled in smooth
muscle as it is in cardiomyocytes.10 17 31 41 95 As mentioned
above, IP3 induces Ca2+ transients by activation of the IP3R
release channel in the SR. The activity of the voltage-gated
L-type Ca2+-channel with the smooth muscle-speci®c
Cav1.2b subunit is modulated by PKA, PKC, CaM and
Ca2+ in a similar way to the modulation of the cardiomyo-
cyte species Cav1.2a. For many years it was not clear
whether membrane-delimited G-proteins (Gas and/or Gbg)
might be involved in Ca2+-channel regulation. However,
newer experimental evidence rejects this possibility.
Interestingly, most of the L-type Ca2+-channels are found
in surface membrane caveolae closely packed together with
the Na+±Ca2+-exchanger (NCX1), the Na+±K+ pump, the
sarcolemmal Ca2+ pump (PMCA) and the large-conduc-
tance Ca2+-activated potassium channel (BKCa). These
caveolae thus assemble the key players in Ca2+ handling and
are, furthermore, in close proximity to parts of the SR.
The smooth muscle L-type Ca2+-channel mainly serves to
®ll and maintain the Ca2+ content of the SR (Fig. 5). As in
myocytes, the Ca2+-channel is activated by PKA phos-
phorylation induced by b-AR stimulation, increasing
cAMP. PKA is recruited to the membrane for Ca2+-channel
phosphorylation by the PKA-anchoring protein AKAP. At
high concentrations of cAMP, the Ca2+-channel stimulation
by PKA may, however, be attenuated for the following
reasons. PKG is an important mediator of vascular relax-
ation induced by the endothelial derived relaxing factor
nitric oxide (NO), which stimulates the cytoplasmic
guanylyl cyclase (GC) by interaction with its haem group
and produces cGMP.2,47 cGMP activates PKG, which
lowers intracellular Ca2+ by inhibition of the L-type Ca2+-
channel, activates the BKCa (see below), and also activates
the MLCP (Fig. 5). Whether inhibition of the Ca2+-channel
is achieved by direct phosphorylation of the Cav1.2b
subunit or by activation of a protein phosphatase is not
clear at present. To complicate matters further, neither
cAMP nor cGMP displays absolute speci®city for its
respective kinase. Thus, some of the actions of cAMP at
high concentrations may be due to stimulation of both PKA
(channel activation) as well as of PKG (channel inhibition).
One of the most salient features of the caveolae arrange-
ment for the regulation of Ca2+ entry into the cell rests on
the close juxtaposition with the SR.10 15 47 81 Calcium entry
locally activates the RYR release channel of the SR and thus
triggers so-called Ca2+ sparks, which in turn activate the
BKCa channel in the caveolar vicinity. The BKCa consists
of the channel-forming a-subunit (125 kDa) and a small
regulatory b-subunit (21.5 kDa). The b-subunit is select-
ively expressed in smooth muscle, localizes to the intra-
cellular side of the channel, and markedly increases the
Ca2+-sensitivity of the channel complex. PKA and PKG
seem to stimulate whereas PKC may inhibit the BKCa
channel activity. The BKCa is activated either by elevation
of the intracellular Ca2+ or by diminishing the membrane
potential. Together with the voltage-dependent K+-chan-
nels, it is mostly responsible for the membrane or resting
potential. The caveolar Ca2+ pathway over the short
distances from the L-type Ca2+-channel to the SR and
from the RYR of the SR back to the sarcolemmal BKCa
represents a feedback loop where Ca2+ entry leads imme-
diately to a more negative resting potential. This arises by
activation of the potassium out¯ow through the BKCa
shielding the cell from undue Ca2+ entry. The BKCa seems
not to be present in the myocyte surface membrane.
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As mentioned above for the integrin-ILK signalling for
phosphorylation of myosin RLC and MLCP, integrin-
dependent signalling involving a tyrosine phosphorylation
cascade can also activate the L-type Ca2+-channel. This
signalling pathway may translate mechanical forces of the
ECM-linked integrins directly to an increase in Ca2+ entry,
leading to an increase in vascular tone.
Hallmarks of smooth muscle versus
myocardial regulation
The following characteristics differentiate smooth muscle
regulation from that of the myocardium. (i) Smooth muscle
contraction and relaxation are slow processes (in the range
of seconds to minutes) compared with heart muscle (in the
range of milliseconds). In heart muscle the on±off switch is
effected by allosteric conformational changes in the
contractile protein complex (myosin-II, actin, troponin and
tropomyosin), by fast and reversible binding of Ca2+
to cardiac TnC. Regulation in smooth muscle operates
exclusively via covalent protein modi®cation by reversible
phosphorylation of myosin RLC and/or actin ®lament
components. These processes require the activation of
enzyme systems for sequential phosphorylation and dephos-
phorylation steps. (ii) Vascular smooth muscle tone can be
achieved by various agonists via GPCR and Gaq-induced
signalling in a Ca2+-independent manner. The degree of
vasoconstriction depends primarily on the activity ratio
between MLCK and MLCP. The term `Ca2+-sensitization'
(an increase in force without an increase in cytoplasmic
Ca2+) is referred to in the context of inhibition of the MLCP.
(iii) Smooth muscle tone depends on very slow turnover of
the myosin crossbridges with a low degree of phosphoryl-
ation and, consequently, low ATP consumption (an energy-
saving mechanism). (iv) In large conduit arteries it seems
that force maintenance depends predominantly on actin
®lament regulation. In contrast, in small resistance arteries
the a1-AR-mediated signalling via the Rho±ROK pathway,
resulting in Ca2+-sensitization of myosin-II, appears to
prevail. (v) Unlike in heart muscle, where b-AR signalling
increases total intracellular Ca2+ in proportion to the
inotropic effect, in vascular smooth muscle b-AR signalling
leads to relaxation by inhibiting the activation of myosin-II,
independent of the cellular Ca2+. This last point represents
the basis for understanding some of the major unwanted side
effects of b-AR blocker treatment, such as peripheral
vasoconstriction, increased bronchial resistance and the risk
Table 1 Main adrenergic receptor subtype signalling and functions in nervous, cardiac and vascular tissues. CNS, central nervous system; for signalling
components consult legends to Figures 1±3. Literature references are given in the text
Adrenergic receptor subtype Main signalling pathways
(compare Figs 1±3, and 5±6)
Adrenergic functions
b1 Gs±AC±cAMP±PKA Positive effects on heart rate, inotropy,
lusitropy, metabolism, growth, and
myocyte toxicity
b2 Gs±AC±cAMP±PKA, and
Gi±PLC±DAG±PKC, and
Gbg±PI3K±PDK1±PKB
Positive effects on inotropy, lusitropy,
metabolism, growth, and myocyte survival
Presynaptic stimulation of NA release
Relaxation of
bronchial and vascular
smooth muscle cells
b3 Gi±PLC±DAG±PKC, and
Gi±NOS±NO±GC±cGMP±PKG
Negative inotropy, and myocyte survival
a1A Gq±PLC±IP3±Ca2+, also
Rho±Rho kinase also ERK, JNK, p38
Positive effects on heart rate, inotropy
and growth in myocytes
Vasoconstriction
a1B Gq±PLC±IP3±Ca2+, also
ERK, p38 (not JNK)
Positive effects on heart rate, inotropy,
and growth in myocytes
Vasoconstriction
a1D Gq±PLC±IP3±Ca2+,
only weakly MAPKs
Mainly in vascular
smooth muscle cells,
vasoconstriction
a2A Gi±inhibiting AC Presynaptically reduces sympathetic out¯ow
at high frequency nerve activity
Lowers blood pressure
a2B Gi±inhibiting AC Postsynaptically counteracts the effects of
alpha2A
Vasoconstriction in
the periphery, in the
CNS salt-induced
hypertension
a2C Gi±inhibiting AC Presynaptically reduces basal sympathetic
out¯ow at low frequency nerve activity
Lowers blood pressure
Postsynaptically lowers cAMP Participation in
vasoconstriction after
exposure to cold
temperatures
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of hypoglycaemia with diabetes mellitus. On the other hand,
the treatment of asthma with b2-AR agonists for broncho-
dilatation may entail tachycardia (Table 1).
Interplay between calcium and adrenergic
receptor subtype-speci®c signalling
In general, the type-2 ARs (a2 and b2) are found at the
prejunctional site in the central and peripheral sympathetic
nervous system, where activation of a2-AR inhibits and
activation of b2-AR enhances noradrenaline release, both
being of pharmacological signi®cance (Fig. 6). In most
effector cells, such as cardiomyocytes, endothelial and
smooth muscle cells, the type-2 ARs are also present
postsynaptically together with a1, b1 and b3-ARs (Figs 1
and 6). Stimulation of the a2-ARs lowers intracellular Ca2+
by activation of Gai-proteins, inhibition of the AC,
activation of sarcolemmal inwardly rectifying K+-channels,
and inhibition of the L-type Ca2+-channels, resulting in
lowering of the Ca2+-dependent noradrenaline release from
the presynaptic transmitter vesicles (Table 1).
Presynaptically localized a2A-AR and a2C-AR subtypes
are important in lowering sympathetic tone in the central
nervous system and in decreasing noradrenaline release in
cardiac sympathetic nerve terminals.24 69 74 Use of the
isotope dilution method demonstrated that the sympathetic
out¯ow in chronically failing hearts is greatly enhanced
with a cardiac noradrenaline spillover, being increased by as
much as 50-fold. On the other hand, the stimulation level of
cardiac sympathetic nerves is one of the most powerful
predictors of mortality.19 The a2-AR agonists clonidine and
dexmedetomidine are non-subtype-selective. They are used
to treat patients with hypertension, glaucoma (local appli-
cation), tumour pain or postoperative pain, and to block
sympathetic overactivity during opioid withdrawal.68 80
While postsynaptic a2B-ARs are responsible for the short-
term hypertensive effect of a2-agonists (vasoconstriction
but concomitant nitric oxide release), postsynaptic a2A-ARs
mediate primarily the sympathetic tone of the central
nervous system. However, there are no direct a2-AR-
mediated effects on the myocardium.
The b-ARs are the key regulators of heart rate, systolic
and diastolic function, and myocardial metabolism.
Extracellular adrenergic stimuli (catecholamines) intermin-
gle with intracellular Ca2+ signalling. Not only is Ca2+ a key
intracellular messenger for many signalling components,
but its own spatiotemporal signalling transients are
decisively in¯uenced by the G-protein coupled b-ARs. An
integrated view of the complex interplay between adrener-
gic and Ca2+ signalling is schematized in Figs 1±3 and 5.
Acute changes in myocardial function are almost exclu-
sively governed by the b-AR signalling pathways. A
functionally relevant contribution of a1-ARs appears
unlikely in humans under normal conditions. However, in
heart failure, b-ARs are desensitized and downregulated
(b1>b2), whereas the total amount of a1-AR subtypes
remains constant or may even be upregulated. Under these
conditions, the a1-AR-mediated inotropy may prove
important.11 54 74 92 In the rat myocardium, a1A- and a1B-
ARs display signi®cant positive effects on inotropy, heart
rate and growth (Table 1). Positive inotropy by these two
a1-AR subtypes was also shown for mouse, hamster, guinea
pig, rabbit and dog. It was recently shown that the positive
inotropic response of rat papillary muscle to stimulation of
the a1A-AR subtype is primarily due to myosin RLC
phosphorylation by MLCK.1 This RLC phosphorylation
depends neither on cAMP nor on PKC activation, and the
cytoplasmic Ca2+ is only moderately increased. RLC
phosphorylation sensitizes the contractile apparatus to
Ca2+, i.e. enhanced contraction in the presence of un-
changed cytoplasmic Ca2+ concentration. Similar observa-
tions were made with endothelin stimulation. Taking these
observations together, it is hypothesized that in myocytes
the positive inotropy elicited by a1-ARs, in general,
depends on the signalling cascade Gaq±PLC±IP3±Ca2+±
CaM and subsequent phosphorylation of the myosin RLC
by MLCK. This is in contrast to the smooth muscle, where
the a1-mediated increase of contractility is mainly achieved
by inhibition of the MLCP system by the Rho±ROK
pathway and by activation of speci®c PKC isoforms (Fig. 5).
All three a1-AR subtypes are found in smooth muscle cells
and mediate vasoconstriction (Table 1).2 11 24 47 69
An interesting aspect concerns the signalling differences
between b1- and b2-AR. Although both b1-ARs and b2-ARs
increase contractile amplitude and hasten relaxation in
ventricular myocytes, several striking differences with
respect to signal transduction downstream from the b-ARs
have been revealed. While b1-AR signalling strictly adheres
to the canonical cAMP±PKA pathway, the b2-AR adopts a
much more ¯exible approach by being able to signal via
Gas, Gai, Gaq and/or Gbg depending on spatiotemporal
Fig 6 Schematic representation of adrenergic synaptic transmission in the
central and peripheral nervous system and at the site of target tissues.
The effector cells may comprise cardiomyocytes, smooth muscle cells or
endothelial cells. NA=noradrenaline; SNS=sympathetic nervous system;
TV=transmitter vesicle. Line with blunted end (=) indicates inhibition.
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relations in the receptor microenvironment (Fig. 1). It was
demonstrated that apoptotic myocyte cell death is dis-
sociated from b2-AR and selectively mediated by b1-AR in
isolated ventricular myocytes and in intact hearts
in vivo.96 98 99 The possible activation of different G-
proteins by b2-ARs may result in distinct downstream
signalling pathways. The chronic catecholamine-dependent
positive inotropy of b2-AR is supported by an increased
Ca2+ in¯ux via the L-type Ca2+-channel without cardiotoxic
consequences. This is achieved by locally restricted
signalling to the Ca2+-channel located close by in the
membrane, and bypasses the b1-typical effects on PLN and
the contractile proteins. On the other hand, coupling to Gai/
Gbg activates several cytoprotective mechanisms (counter-
acting in part the Gas-mediated routes), such as activation
of ATP-dependent K+-channels in the sarcolemma and in
the inner mitochondrial membrane, mediated by different
PKC isoforms, and activation of the protein kinase B (PKB,
also called Akt). In the latter case, signalling proceeds via
the PI3K and PI3K-dependent kinase-1 (PDK1) pathway
(Fig. 1). PKB activation leads to increased expression of the
antiapoptotic protein Bcl-2 and inhibition of proapoptotic
factors, such as caspase-9 and Fas-ligand expression.
Activation of the endothelial nitric oxide synthase
(eNOS), which is constitutively expressed in cardiomyo-
cytes, greatly depends on b3-AR signalling and leads to
activation of the cGMP-dependent PKG.2 47 90 NO may also
reach the myocytes from extracellular sources, such as the
endothelial cells. Thus, NO operates in both autocrine and
paracrine fashions. The NO±GC±cGMP±PKG pathway also
exerts a negative inotropic effect in the myocytes by
reducing Ca2+ in¯ux through L-type Ca2+-channels. This
negative inotropic effect of the b3-AR acts under normal
conditions as a negative counter-regulation. In contrast, in
the failing heart, where b3-ARs are upregulated with
concomitant downregulation of b1-ARs, this negative
inotropic effect may aggravate the deterioration of cardiac
function.
Conclusions
Insight into the complex sympathetic regulatory mechan-
isms may not only allow better therapeutic approaches in
perioperative medicine, but may also help explain the
clinically observed unwanted or unexpected side-effects
that may occur when using pharmacological modulators of
AR activity. Some of the relevant new properties that we
have discussed are adrenergic receptor signalling via
different types of G-proteins, homologous and heterologous
desensitization of ARs, the homo- and heterodimerization of
AR-subtypes, and the downstream signalling network
connected to the different adrenergically modulated cellular
functions. Adrenergic signalling relies in principal on two
intracellular signalling modes: (i) reversible binding of Ca2+
ions to speci®c protein sites; and (ii) several different
protein phosphorylation cascades. These two signalling
modes follow distinct pathways, which are intimately
interlinked. On the one hand, the signalling crosstalk entails
considerable redundancy, securing cardiac function under
abruptly changing or even adverse conditions. On the other
hand, it reveals a ®ne-tuning of regulation that is well suited
for differentiated pharmacological interventions. What have
not been dealt with in this review are the human
polymorphisms in adrenergic receptors and in their down-
stream signalling components that have recently come to
light; these may affect the established adrenergic signalling
in some cases. In conclusion, a detailed understanding of the
basic adrenergic functions in cardiac and vascular tissues is
indispensable for the development of new perioperative
therapeutic strategies and will foster the testing of novel
hypotheses in randomized clinical trials.
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